|
FR104E
(fr)
|
|
|
|
|
|
US5843708A
(en)
|
1988-01-05 |
1998-12-01 |
Ciba-Geigy Corporation |
Chimeric antibodies
|
|
WO1990005144A1
(fr)
|
1988-11-11 |
1990-05-17 |
Medical Research Council |
Ligands a domaine unique, recepteurs comprenant lesdits ligands, procedes pour leur production, et emploi desdits ligands et recepteurs
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
AU7579291A
(en)
|
1990-04-16 |
1991-11-11 |
United States of America, as represented by the Secretary, U.S. Department of Commerce, The |
Use of purinergic receptor agonists as antineoplastic agents
|
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
|
US5397703A
(en)
|
1992-07-09 |
1995-03-14 |
Cetus Oncology Corporation |
Method for generation of antibodies to cell surface molecules
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
US5900407A
(en)
|
1997-02-06 |
1999-05-04 |
Inspire Pharmaceuticals, Inc. |
Method of treating dry eye disease with uridine triphosphates and related compounds
|
|
US5898031A
(en)
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
|
DE19939653A1
(de)
|
1999-08-13 |
2001-02-22 |
Thomas Huenig |
Verwendung CD28 spezifischer monoklonaler Antikörper zur Herstellung einer pharmazeutischen Zusammensetzung
|
|
JP3871503B2
(ja)
|
1999-08-30 |
2007-01-24 |
日本たばこ産業株式会社 |
免疫性疾患治療剤
|
|
JP4210454B2
(ja)
|
2001-03-27 |
2009-01-21 |
日本たばこ産業株式会社 |
炎症性腸疾患治療剤
|
|
ATE363290T1
(de)
|
1999-10-04 |
2007-06-15 |
Novartis Vaccines & Diagnostic |
Cd40 antagonist zur behandlung von psoriasis
|
|
MXPA02005161A
(es)
|
1999-12-22 |
2002-12-09 |
Inspire Pharmaceuticals Inc |
Metodo para tratamiento de enfermedades del aparato gastrointestinal con agonistas de los receptores purinergicos.
|
|
US7034121B2
(en)
|
2000-01-27 |
2006-04-25 |
Genetics Institue, Llc |
Antibodies against CTLA4
|
|
WO2002011763A1
(fr)
|
2000-04-19 |
2002-02-14 |
Tanox, Inc. |
Antagonistes de cd40 destines au traitement du psoriasis et d'autres inflammations cutanees
|
|
US20030059427A1
(en)
|
2000-04-28 |
2003-03-27 |
Force Walker R. |
Isolation and characterization of highly active anti-CD40 antibody
|
|
JP3597140B2
(ja)
|
2000-05-18 |
2004-12-02 |
日本たばこ産業株式会社 |
副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
|
|
CA2424296A1
(fr)
|
2000-10-02 |
2002-04-11 |
Chiron Corporation |
Anticorps humains diriges contre cd40
|
|
DE10050935A1
(de)
|
2000-10-11 |
2002-05-02 |
Tegenero Gmbh |
Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen
|
|
US8414892B2
(en)
|
2000-10-18 |
2013-04-09 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8H9
|
|
US8501471B2
(en)
|
2000-10-18 |
2013-08-06 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8H9
|
|
US20020102264A1
(en)
|
2000-10-18 |
2002-08-01 |
Cheung Nai-Kong V. |
Uses of monoclonal antibody 8H9
|
|
EP1399187A4
(fr)
|
2000-10-18 |
2005-09-21 |
Sloan Kettering Inst Cancer |
Utilisations d'anticorps monoclonal 8h9
|
|
JP2004515243A
(ja)
|
2000-12-14 |
2004-05-27 |
藤沢薬品工業株式会社 |
サイレント抗ｃｄ２８抗体およびその使用
|
|
JP4066166B2
(ja)
|
2000-12-26 |
2008-03-26 |
アンスティテュ ナシオナル ド ラ サント エ ド ラ ルシュルシェ メディカル（アンセルム） |
抗−ｃｄ２８抗体
|
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
|
EP2009027B1
(fr)
|
2001-04-27 |
2014-05-21 |
Kyowa Hakko Kirin Co., Ltd. |
Anticorps monoclonal anti-CD40
|
|
WO2003028712A2
(fr)
*
|
2001-09-28 |
2003-04-10 |
Universite Libre De Bruxelles |
Agonistes de recepteur purinergique et pyrimidinergique pour le traitement de maladies immunitaires mediees par le lymphocyte t cd4+ active
|
|
WO2003029296A1
(fr)
|
2001-10-02 |
2003-04-10 |
Chiron Corporation |
Anticorps humains diriges contre le cd40
|
|
AR039067A1
(es)
|
2001-11-09 |
2005-02-09 |
Pfizer Prod Inc |
Anticuerpos para cd40
|
|
PA8557501A1
(es)
|
2001-11-12 |
2003-06-30 |
Pfizer Prod Inc |
Benzamida, heteroarilamida y amidas inversas
|
|
AU2002346581A1
(en)
|
2001-11-26 |
2003-06-10 |
Chiron Corporation |
Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
|
|
US20080199471A1
(en)
|
2002-03-01 |
2008-08-21 |
Bernett Matthew J |
Optimized cd40 antibodies and methods of using the same
|
|
AU2003220079A1
(en)
|
2002-03-08 |
2003-09-22 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8h9
|
|
DE10212108A1
(de)
|
2002-03-13 |
2003-10-02 |
Tegenero Ag |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung
|
|
US7550140B2
(en)
|
2002-06-13 |
2009-06-23 |
Crucell Holland B.V. |
Antibody to the human OX40 receptor
|
|
DE10230223A1
(de)
|
2002-07-04 |
2004-01-22 |
Tegenero Ag |
Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern
|
|
US7052694B2
(en)
|
2002-07-16 |
2006-05-30 |
Mayo Foundation For Medical Education And Research |
Dendritic cell potentiation
|
|
WO2004010947A2
(fr)
|
2002-07-30 |
2004-02-05 |
Bristol-Myers Squibb Company |
Anticorps humanises contre le 4-1bb humain
|
|
US7291331B1
(en)
|
2002-09-11 |
2007-11-06 |
La Jolla Institute For Allergy And Immunology |
Methods of treating OX40 medicated recall immune responses
|
|
US7557092B2
(en)
|
2002-11-21 |
2009-07-07 |
University Of Utah Research Foundation |
Purinergic modulation of smell
|
|
JP4511943B2
(ja)
|
2002-12-23 |
2010-07-28 |
ワイス エルエルシー |
Ｐｄ−１に対する抗体およびその使用
|
|
US20070104688A1
(en)
|
2003-02-13 |
2007-05-10 |
City Of Hope |
Small interfering RNA mediated transcriptional gene silencing in mammalian cells
|
|
KR20060052681A
(ko)
|
2003-05-23 |
2006-05-19 |
와이어쓰 |
Ｇｉｔｒ 리간드, ｇｉｔｒ 리간드-연관 분자, 항체 및그의 용도
|
|
US20090191213A9
(en)
|
2003-07-02 |
2009-07-30 |
Novo Nordisk A/S |
Compositions and methods for regulating NK cell activity
|
|
GB0324498D0
(en)
|
2003-07-21 |
2003-11-26 |
Aventis Pharma Inc |
Heterocyclic compounds as P2X7 ion channel blockers
|
|
EP1600164A3
(fr)
|
2003-09-22 |
2006-05-17 |
TeGenero AG |
Utilisation d'une substance liant le CD28 dans la production d'une composition pharmaceutique à effet dose-dépendant
|
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
|
US7923448B2
(en)
|
2003-11-03 |
2011-04-12 |
Cornell Research Foundation, Inc. |
Purine receptor inhibition as a therapeutic strategy in spinal cord and brain
|
|
EP1694360B1
(fr)
|
2003-11-04 |
2010-08-04 |
Novartis Vaccines and Diagnostics, Inc. |
Utilisation d'anticorps antagonistes anti-cd40 pour le traitement de maladies autoimmunes et inflammatoires et le rejet d'organes transplantes
|
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
|
WO2005044305A2
(fr)
|
2003-11-04 |
2005-05-19 |
Chiron Corporation |
Procedes therapeutiques de tumeurs solides exprimant l'antigene de surface cellulaire cd40
|
|
US20070098718A1
(en)
|
2003-11-04 |
2007-05-03 |
Chiron |
Methods of therapy for b cell-related cancers
|
|
PL1684805T3
(pl)
|
2003-11-04 |
2010-12-31 |
Novartis Vaccines & Diagnostics Inc |
Sposoby leczenia szpiczaka mnogiego z zastosowaniem antagonistycznych monoklonalnych przeciwciał przeciwko CD40
|
|
JP4765037B2
(ja)
|
2003-11-04 |
2011-09-07 |
ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド |
慢性リンパ球性白血病の処置のためのアンタゴニスト抗ｃｄ４０モノクローナル抗体の使用
|
|
DE10352900A1
(de)
|
2003-11-11 |
2005-06-16 |
Tegenero Ag |
Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL
|
|
US20050136055A1
(en)
|
2003-12-22 |
2005-06-23 |
Pfizer Inc |
CD40 antibody formulation and methods
|
|
PL1707627T3
(pl)
|
2003-12-25 |
2013-04-30 |
Kyowa Hakko Kirin Co Ltd |
Mutant antagonistycznego przeciwciała anty-CD40
|
|
JP2007535553A
(ja)
|
2004-04-29 |
2007-12-06 |
アボット・ラボラトリーズ |
アミノ−テトラゾール類縁体および使用方法
|
|
US20050261239A1
(en)
*
|
2004-05-23 |
2005-11-24 |
Universiteit Van Maastricht |
Use of ATP for the manufacture of a medicament for treating certain inflammatory conditions, oxidative stress and fatigue
|
|
US20060099203A1
(en)
|
2004-11-05 |
2006-05-11 |
Pease Larry R |
B7-DC binding antibody
|
|
EP2287195B1
(fr)
|
2004-07-01 |
2019-05-15 |
Novo Nordisk A/S |
Anticorps contre le Pan-KIR2DL NK-recepteur et leur utilsation diagnostique at therapeutique
|
|
US20080057070A1
(en)
|
2004-11-04 |
2008-03-06 |
Chiron Corporation |
Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
|
|
DE102004063494A1
(de)
|
2004-12-23 |
2006-07-13 |
Tegenero Ag |
Antikörper
|
|
PT1836225E
(pt)
|
2005-01-06 |
2012-01-10 |
Novo Nordisk As |
Agentes de ligação a kir e métodos de utilização dos mesmos
|
|
DK1835937T3
(da)
|
2005-01-06 |
2012-07-23 |
Novo Nordisk As |
Sammensætninger og fremgangsmåder til behandling af virusinfektion
|
|
US20090196850A1
(en)
|
2005-01-06 |
2009-08-06 |
Novo Nordisk A/S |
Anti-Kir Combination Treatments and Methods
|
|
US8759490B2
(en)
|
2005-03-24 |
2014-06-24 |
Millennium Pharamaceuticals, Inc. |
Antibodies that bind OV064 and methods of use therefor
|
|
WO2006104677A2
(fr)
|
2005-03-24 |
2006-10-05 |
Millennium Pharmaceuticals, Inc. |
Anticorps se liant a ov064 et leurs methodes d'utilisation
|
|
CA2602777C
(fr)
|
2005-03-25 |
2018-12-11 |
Tolerrx, Inc. |
Molecules de liaison gitr et leurs utilisations
|
|
US20060240006A1
(en)
|
2005-04-20 |
2006-10-26 |
Chishih Chu |
Novel antibody structures derived from human germline sequences
|
|
CA2605745A1
(fr)
|
2005-04-27 |
2006-11-02 |
Robert J. Hickey |
Anticorps de l'isoforme de l'antigene nucleaire des cellules proliferatives cancereuses specifiques (pcnacs) et leurs utilisations
|
|
PL2161336T5
(pl)
|
2005-05-09 |
2017-10-31 |
Ono Pharmaceutical Co |
Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
|
|
US7585960B2
(en)
|
2005-05-11 |
2009-09-08 |
Theramab Gmbh |
Nucleic acids encoding superagonistic anti-CD28 antibodies
|
|
EP1894012A2
(fr)
|
2005-05-18 |
2008-03-05 |
Novartis AG |
Methodes de diagnostic et de traitement des maladies proliferatives mediees par la signalisation cd40
|
|
CA2608750A1
(fr)
|
2005-05-18 |
2006-11-23 |
Novartis Ag |
Procedes de diagnostic et de traitement de maladies ayant une composante auto-immune et/ou inflammatoire
|
|
KR100694508B1
(ko)
|
2005-05-24 |
2007-03-13 |
울산대학교 산학협력단 |
Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
|
|
EP1885399B1
(fr)
|
2005-05-26 |
2010-10-20 |
Seattle Genetics, Inc. |
Anticorps anti-cd40 humanisés et procédés d'utilisation
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
US8926979B2
(en)
|
2005-11-01 |
2015-01-06 |
Novartis Ag |
Treatment of cancer or pre-malignant conditions using anti-CD40 antibodies
|
|
AU2006308860B2
(en)
|
2005-11-01 |
2012-01-12 |
Novartis Ag |
Uses of anti-CD40 antibodies
|
|
WO2007056046A1
(fr)
|
2005-11-07 |
2007-05-18 |
Abbott Laboratories |
Antagonistes des recepteurs p2x7 et methodes d'utilisation
|
|
TWI461436B
(zh)
|
2005-11-25 |
2014-11-21 |
Kyowa Hakko Kirin Co Ltd |
人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
|
|
CA2630483C
(fr)
|
2005-12-08 |
2015-05-19 |
Medarex, Inc. |
Anticorps monoclonaux humains se fixant a l'o8e
|
|
WO2007075326A2
(fr)
|
2005-12-09 |
2007-07-05 |
Seattle Genetics, Inc. |
Procédés d'utilisation d'agents de liaison de cd40
|
|
US20110008368A1
(en)
|
2006-01-13 |
2011-01-13 |
Board Of Regents, The University Of Texas System |
Methods of modulating the ox40 receptor to treat cancer
|
|
WO2007109201A2
(fr)
|
2006-03-16 |
2007-09-27 |
Renovis, Inc. |
Composés de bicyclohétéroaryle en tant que modulateur de p2x7 et leurs utilisations
|
|
NZ571757A
(en)
|
2006-04-21 |
2012-01-12 |
Novartis Ag |
Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
|
|
EP1854810A1
(fr)
|
2006-05-09 |
2007-11-14 |
PanGenetics B.V. |
Anticorps monoclonal anti CD40 humain déimmunisé et antagoniste dérivé de l'anticorps ch5D12
|
|
KR100745488B1
(ko)
|
2006-07-04 |
2007-08-02 |
학교법인 울산공업학원 |
항-4-1ｂｂ 항체 및 화학 항암제를 포함하는 암 질환 예방및 치료용 약학 조성물
|
|
AU2007306924A1
(en)
|
2006-10-10 |
2008-04-17 |
Biosceptre International Limited |
Hybridomas producing antibodies against non functional P2X7 receptor
|
|
GB0620894D0
(en)
|
2006-10-20 |
2006-11-29 |
Univ Southampton |
Human immune therapies using a CD27 agonist alone or in combination with other immune modulators
|
|
AU2007334264A1
(en)
|
2006-11-15 |
2008-06-26 |
Medarex, Inc. |
Human monoclonal antibodies to BTLA and methods of use
|
|
ES2579768T3
(es)
|
2007-01-11 |
2016-08-16 |
Novo Nordisk A/S |
Anticuerpos anti-KIR, formulaciones y usos de los mismos
|
|
EP2125893A2
(fr)
|
2007-01-23 |
2009-12-02 |
Xencor, Inc. |
Anticorps cd40 optimisés et leurs procédés d'utilisation
|
|
MX2009010059A
(es)
|
2007-03-22 |
2009-10-12 |
Astrazeneca Ab |
Derivados de quinolina para el tratamiento de enfermedades inflamatorias.
|
|
US20100143245A1
(en)
|
2007-03-22 |
2010-06-10 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8h9
|
|
JP2010523524A
(ja)
|
2007-04-03 |
2010-07-15 |
グラクソ グループ リミテッド |
Ｐ２ｘ７調節因子としてのイミダゾリジンカルボキサミド誘導体
|
|
WO2008124153A1
(fr)
|
2007-04-10 |
2008-10-16 |
H. Lundbeck A/S |
Analogues d'heteroaryl-amides utilises en tant qu'antagonistes de p2x7
|
|
US20080279851A1
(en)
|
2007-05-07 |
2008-11-13 |
Medlmmune, Llc |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
DE602008005582D1
(de)
|
2007-05-10 |
2011-04-28 |
Glaxo Group Ltd |
Pyrazolderivate als p2x7-modulatoren
|
|
KR20080107050A
(ko)
|
2007-06-05 |
2008-12-10 |
울산대학교 산학협력단 |
항-ｃｄ１３７ 단일클론 항체를 포함하는 만성이식편대숙주 질환의 예방 또는 치료용 약학적 조성물
|
|
CA2691357C
(fr)
|
2007-06-18 |
2014-09-23 |
N.V. Organon |
Anticorps diriges contre le recepteur humain de mort programmee pd-1
|
|
JPWO2009001673A1
(ja)
*
|
2007-06-26 |
2010-08-26 |
学校法人 城西大学 |
Ａｔｐ含有免疫アジュバント
|
|
US20090028857A1
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
|
FR2921342B1
(fr)
|
2007-09-20 |
2010-03-12 |
Airbus France |
Carenage aerodynamique arriere inferieur pour dispositif d'accrochage d'un moteur d'aeronef
|
|
JP2011500767A
(ja)
|
2007-10-26 |
2011-01-06 |
グラクソ グループ リミテッド |
Ｐ２ｘ７モジュレータとしての４−ベンゾイル−１−置換ピペラジン−２−オン誘導体
|
|
MX2010004705A
(es)
|
2007-10-31 |
2010-05-27 |
Nissan Chemical Ind Ltd |
Derivados de piridazinona y uso de los mismos como inhibidores del receptor p2x7.
|
|
CA2705263A1
(fr)
|
2007-11-09 |
2009-05-14 |
Novartis Ag |
Therapie combinee renfermant un anticorps antagoniste anti-cd 40 et du cyclophosphamide, de la doxorubicine, de la vincristine et de la prednisone (chop) en vue du traitement de cellules malignes de type b
|
|
US8106073B2
(en)
|
2007-11-30 |
2012-01-31 |
Astrazeneca Ab |
Quinoline derivatives 057
|
|
AU2008334063A1
(en)
|
2007-11-30 |
2009-06-11 |
Bristol-Myers Squibb Company |
Anti-B7H4 monoclonal antibody-drug conjugate and methods of use
|
|
JP5635412B2
(ja)
|
2007-12-04 |
2014-12-03 |
アルニラム ファーマスーティカルズ インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
標的化脂質
|
|
AU2009206506B2
(en)
|
2008-01-23 |
2013-01-10 |
Xencor, Inc. |
Optimized CD40 antibodies and methods of using the same
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
US8314068B2
(en)
|
2008-04-14 |
2012-11-20 |
University Hospitals Of Cleveland |
P2X7 inhibition of epithelial cancers and papillomas
|
|
ES2376092T3
(es)
|
2008-04-22 |
2012-03-08 |
Janssen Pharmaceutica, N.V. |
Antagonistas de p2x7 sustituidos con quinolina o isoquinolina.
|
|
US20110229460A1
(en)
|
2008-05-01 |
2011-09-22 |
Gtc Biotherapeutics, Inc. |
anti-cd137 antibody as an agent in the treatment of inflammatory conditions
|
|
KR20110039220A
(ko)
|
2008-06-30 |
2011-04-15 |
교와 핫꼬 기린 가부시키가이샤 |
항ｃｄ27 항체
|
|
ES2890230T3
(es)
|
2008-07-16 |
2022-01-18 |
Baylor Res Institute |
Vacuna contra el VIH basada en el direccionamiento de Gag y Nef maximizado a células dendríticas
|
|
JP2012507260A
(ja)
|
2008-07-18 |
2012-03-29 |
ドマンティス リミテッド |
Ｃｄ２８結合のための一価の組成物及び使用方法
|
|
AR072571A1
(es)
|
2008-07-18 |
2010-09-08 |
Bristol Myers Squibb Co |
Composiciones monovalentes para union a cd28 y procedimientos de uso
|
|
US20110097339A1
(en)
|
2008-07-18 |
2011-04-28 |
Domantis Limited |
Compositions monovalent for CD28 binding and methods of use
|
|
CA2736829C
(fr)
|
2008-09-12 |
2018-02-27 |
Isis Innovation Limited |
Anticorps specifiques de pd-1 et leurs utilisations
|
|
EP2342228B1
(fr)
|
2008-09-12 |
2017-09-06 |
Oxford University Innovation Limited |
Anticorps spécifiques de pd-1 et leurs utilisations
|
|
CA2998281C
(fr)
|
2008-09-26 |
2022-08-16 |
Dana-Farber Cancer Institute, Inc. |
Anticorps anti-pd-1 humains et leurs utilisations
|
|
US8475790B2
(en)
|
2008-10-06 |
2013-07-02 |
Bristol-Myers Squibb Company |
Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
|
|
US8709411B2
(en)
|
2008-12-05 |
2014-04-29 |
Novo Nordisk A/S |
Combination therapy to enhance NK cell mediated cytotoxicity
|
|
EP4331604B9
(fr)
|
2008-12-09 |
2025-07-23 |
F. Hoffmann-La Roche AG |
Anticorps anti-pd-l1 et leur utilisation pour améliorer la fonction des lymphocytes t
|
|
EP2198873A1
(fr)
|
2008-12-18 |
2010-06-23 |
Aposcience AG |
Préparation pharmaceutique renfermant le surnageant de cultures de cellules mononucléaires sanguines
|
|
MX2011008697A
(es)
|
2009-02-17 |
2011-11-18 |
Ucb Pharma Sa |
Moleculas de anticuerpos que tiene especificidad para ox40 humano.
|
|
GB0903325D0
(en)
|
2009-02-26 |
2009-04-08 |
Univ Aberdeen |
Antibody molecules
|
|
EP3219732A1
(fr)
|
2009-03-10 |
2017-09-20 |
Baylor Research Institute |
Vaccins contre le cancer ciblés de cellules présentatrices d'antigène
|
|
CA2754862C
(fr)
|
2009-03-10 |
2019-04-02 |
Baylor Research Institute |
Anticorps anti-cd40 et utilisations de ceux-ci
|
|
GB0906274D0
(en)
|
2009-04-09 |
2009-05-20 |
Ge Healthcare Ltd |
Imaging the central nervous system
|
|
US8647623B2
(en)
|
2009-04-10 |
2014-02-11 |
Kyowa Hakko Kirin Co., Ltd |
Method for treatment of blood tumor using anti-TIM-3 antibody
|
|
HUE028537T2
(en)
|
2009-04-20 |
2016-12-28 |
Kyowa Hakko Kirin Co Ltd |
Built-in amino acid mutation IgG2 antibody
|
|
EP2424869B1
(fr)
|
2009-04-29 |
2016-06-22 |
Glaxo Group Limited |
DÉRIVÉS DE 5,6,7,8-TÉTRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE COMME MODULATEURS DE P2X7
|
|
GB0907515D0
(en)
|
2009-04-30 |
2009-06-10 |
Glaxo Group Ltd |
Compounds
|
|
US20120076722A1
(en)
|
2009-05-14 |
2012-03-29 |
University Of Maryland, Baltimore |
Methods for treating cancers and diseases associated with 4-1bb (cd137) expression
|
|
ES2352780B2
(es)
*
|
2009-06-04 |
2011-09-15 |
Laboratorios Ovejero S.A. |
Lipopolisacárido de ochrobactrum intermedium contra la sepsis.
|
|
EP2459541A1
(fr)
|
2009-07-30 |
2012-06-06 |
F. Hoffmann-La Roche AG |
Amides de dihydropyrimidone utilisés comme modulateurs p2x7
|
|
CA2769473A1
(fr)
|
2009-07-31 |
2011-02-03 |
N.V. Organon |
Anticorps totalement humains diriges contre le btla
|
|
CA2772613C
(fr)
|
2009-09-03 |
2020-03-10 |
Schering Corporation |
Anticorps anti-gitr
|
|
WO2011031063A2
(fr)
|
2009-09-09 |
2011-03-17 |
울산대학교 산학협력단 |
Composition de prévention ou de traitement de troubles métaboliques contenant l'anticorps anti-4-1bb
|
|
US8871760B2
(en)
|
2009-09-21 |
2014-10-28 |
Roche Palo Alto Llc |
[1,2,4]triazolo[3,4-C][1,4]oxazines as P2X7 modulators
|
|
GB0919594D0
(en)
|
2009-11-09 |
2009-12-23 |
Glaxo Group Ltd |
Compounds
|
|
CA2778714C
(fr)
|
2009-11-24 |
2018-02-27 |
Medimmune Limited |
Agents de liaison cibles diriges contre b7-h1
|
|
SG181533A1
(en)
|
2009-12-07 |
2012-07-30 |
Univ Leland Stanford Junior |
Methods for enhancing anti-tumor antibody therapy
|
|
CA2785964C
(fr)
|
2009-12-29 |
2021-03-30 |
Kyowa Hakko Kirin Co., Ltd. |
Anticorps anti-cd27
|
|
KR20110085038A
(ko)
|
2010-01-19 |
2011-07-27 |
울산대학교 산학협력단 |
항 ｃｄ137-항체 및 독소 결합물을 이용한 ｃｄ137 양성세포의 제거방법
|
|
WO2011091078A2
(fr)
|
2010-01-19 |
2011-07-28 |
Xencor, Inc. |
Variants d'anticorps possédant une activité complémentaire accrue
|
|
ES2896149T3
(es)
|
2010-02-18 |
2022-02-24 |
Ose Immunotherapeutics |
Anticuerpos humanizados anti-CD28
|
|
PH12012501751A1
(en)
|
2010-03-04 |
2012-11-12 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
|
SG10201604336VA
(en)
|
2010-03-04 |
2016-07-28 |
Macrogenics Inc |
Antibodies Reactive With B7-H3, Immunologically Active Fragments Thereof And Uses Thereof
|
|
EP2552965A2
(fr)
|
2010-03-31 |
2013-02-06 |
Boehringer Ingelheim International GmbH |
Anticorps anti-cd40
|
|
US9028830B2
(en)
|
2010-04-08 |
2015-05-12 |
JN Biosciences, LLC |
Antibodies to CD122
|
|
NZ602892A
(en)
|
2010-04-13 |
2014-08-29 |
Celldex Therapeutics Inc |
Antibodies that bind human cd27 and uses thereof
|
|
US20120213771A1
(en)
|
2010-04-13 |
2012-08-23 |
Celldex Therapeutics Inc. |
Antibodies that bind human cd27 and uses thereof
|
|
JP5513242B2
(ja)
|
2010-04-28 |
2014-06-04 |
オリンパス株式会社 |
撮像装置
|
|
JP6158511B2
(ja)
|
2010-06-11 |
2017-07-05 |
協和発酵キリン株式会社 |
抗ｔｉｍ−３抗体
|
|
AU2011275749C1
(en)
|
2010-07-09 |
2015-09-17 |
Aduro Biotech Holdings, Europe B.V. |
Agonistic antibody to CD27
|
|
NZ716369A
(en)
|
2010-08-23 |
2017-05-26 |
Univ Texas |
Anti-ox40 antibodies and methods of using the same
|
|
MY177065A
(en)
|
2010-09-09 |
2020-09-03 |
Pfizer |
4-1bb binding molecules
|
|
AU2011302152B2
(en)
|
2010-09-15 |
2015-06-11 |
Alnylam Pharmaceuticals, Inc. |
Modified iRNA agents
|
|
JP2013249256A
(ja)
|
2010-09-15 |
2013-12-12 |
Astellas Pharma Inc |
脂肪性肝疾患治療薬
|
|
AR083847A1
(es)
|
2010-11-15 |
2013-03-27 |
Novartis Ag |
Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
|
|
EA035033B1
(ru)
|
2010-11-22 |
2020-04-20 |
Иннейт Фарма Са |
Способ лечения гематологического предракового или гематологического ракового заболеваний
|
|
WO2012075111A1
(fr)
|
2010-11-30 |
2012-06-07 |
Novartis Ag |
Utilisation d'anticorps anti-cd40 en thérapie combinée contre des cancers associés aux cellules b
|
|
US20120149718A1
(en)
|
2010-12-14 |
2012-06-14 |
Brotherton-Pleiss Christine E |
Amido Compounds
|
|
US20120157494A1
(en)
|
2010-12-16 |
2012-06-21 |
Harris Iii Ralph New |
Isoindolyl compounds
|
|
EP2656073A4
(fr)
|
2010-12-20 |
2014-12-17 |
Univ Rockefeller |
Modulation d'anticorps agonistes anti-tnfr
|
|
US9956236B2
(en)
|
2011-02-07 |
2018-05-01 |
Cornell University |
Methods for increasing immune responses using agents that directly bind to and activate IRE-1
|
|
WO2012111762A1
(fr)
|
2011-02-17 |
2012-08-23 |
協和発酵キリン株式会社 |
Préparation pharmaceutique d'anticorps anti-cd40 très concentrée
|
|
CA2824415A1
(fr)
|
2011-02-22 |
2012-08-30 |
Actelion Pharmaceuticals Ltd |
Derives de benzamide en tant qu'antagonistes du recepteur p2x7
|
|
GB201103955D0
(en)
|
2011-03-09 |
2011-04-20 |
Antitope Ltd |
Antibodies
|
|
FI3556774T3
(fi)
|
2011-03-11 |
2024-03-15 |
Beth Israel Deaconess Medical Ct Inc |
Anti-cd40-vasta-aineita ja niiden käyttötapoja
|
|
ES2612914T3
(es)
|
2011-03-31 |
2017-05-19 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Anticuerpos dirigidos contra Icos y usos de los mismos
|
|
ES2724801T3
(es)
|
2011-04-19 |
2019-09-16 |
Pfizer |
Combinaciones de anticuerpos anti-4-1BB y anticuerpos inductores de ADCC para el tratamiento del cáncer
|
|
PT2699264T
(pt)
|
2011-04-20 |
2018-05-23 |
Medimmune Llc |
Anticorpos e outras moléculas que ligam b7-h1 e pd-1
|
|
ES2664619T3
(es)
|
2011-04-21 |
2018-04-20 |
Bristol-Myers Squibb Company |
Polipéptidos de anticuerpos que antagonizan CD40
|
|
RS57279B1
(sr)
|
2011-04-25 |
2018-08-31 |
Daiichi Sankyo Co Ltd |
Anti-b7-h3 antitelo
|
|
EP2701719A4
(fr)
|
2011-04-28 |
2015-04-22 |
Claire Mitchell |
Méthode de traitement d'une dégénérescence maculaire par la modulation des récepteurs p2y12 ou p2x7
|
|
US8778345B2
(en)
|
2011-04-29 |
2014-07-15 |
Apexigen, Inc. |
Anti-CD40 antibodies
|
|
CA2837184C
(fr)
|
2011-05-25 |
2021-09-21 |
Innate Pharma, S.A. |
Anticorps anti-kir destines au traitement de troubles inflammatoires
|
|
WO2013006490A2
(fr)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Anticorps se liant spécifiquement à tim3
|
|
CN103702683B
(zh)
|
2011-07-01 |
2017-07-04 |
生物权威(澳大利亚)有限责任公司 |
联合治疗
|
|
EA036047B1
(ru)
|
2011-07-11 |
2020-09-18 |
Икнос Сайенсиз Са |
Антитела, которые связываются с ox40, и их применение
|
|
US9221832B2
(en)
|
2011-07-22 |
2015-12-29 |
Actelion Pharmaceuticals Ltd. |
Heterocyclic amide derivatives as P2X7 receptor antagonists
|
|
US9676854B2
(en)
|
2011-08-15 |
2017-06-13 |
Medimmune, Llc |
Anti-B7-H4 antibodies and their uses
|
|
CA2845810C
(fr)
|
2011-08-23 |
2017-03-28 |
Board Of Regents, The University Of Texas System |
Anticorps anti-ox40 et leurs procedes d'utilisation
|
|
GB201115280D0
(en)
|
2011-09-05 |
2011-10-19 |
Alligator Bioscience Ab |
Antibodies, uses and methods
|
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
|
EP2773651B1
(fr)
|
2011-11-03 |
2020-12-23 |
The Trustees of the University of Pennsylvania |
Compositions spécifiques de b7-h4 isolé et procédés d'utilisation associés
|
|
UA112203C2
(uk)
|
2011-11-11 |
2016-08-10 |
Юсб Фарма С.А. |
Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
|
|
EP2604265A1
(fr)
|
2011-12-17 |
2013-06-19 |
Royal College of Surgeons in Ireland (RCSI) |
Antagonistes P2x7 en tant que traitement auxiliaire ou principal contre l'état de mal épileptique
|
|
HK1206251A1
(en)
|
2012-03-15 |
2016-01-08 |
Janssen Biotech, Inc. |
Human anti-cd27 antibodies, methods and uses
|
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
|
JP2015519375A
(ja)
|
2012-05-31 |
2015-07-09 |
ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． |
Ｐｄ−ｌ１に結合する抗原結合蛋白質
|
|
KR101549637B1
(ko)
|
2012-06-08 |
2015-09-03 |
국립암센터 |
신규한 Ｔｈ1 세포 전환용 에피토프 및 이의 용도
|
|
CN104507538B
(zh)
|
2012-06-08 |
2018-04-06 |
艾杜罗生物科技公司 |
癌症免疫疗法的组合物和方法
|
|
US9268936B2
(en)
|
2012-07-27 |
2016-02-23 |
Mandiant, Llc |
Physical memory forensics system and method
|
|
WO2014022758A1
(fr)
|
2012-08-03 |
2014-02-06 |
Dana-Farber Cancer Institute, Inc. |
Anticorps de liaison double à agent unique anti-pd-l1 et pd-l2 et procédés d'utilisation
|
|
ES2684552T3
(es)
|
2012-09-03 |
2018-10-03 |
Inserm - Institut National De La Santé Et De La Recherche Médicale |
Anticuerpos dirigidos contra ICOS para tratar la enfermedad de injerto contra hospedador
|
|
EP3263601B1
(fr)
|
2012-10-02 |
2021-11-24 |
Bristol-Myers Squibb Company |
Combinaison d'anticorps anti-kir et anti-pd-1 pour traiter le cancer
|
|
KR102853456B1
(ko)
|
2012-10-11 |
2025-09-01 |
다이이찌 산쿄 가부시키가이샤 |
글리신아미드 화합물의 제조 방법
|
|
TWI598325B
(zh)
|
2012-10-12 |
2017-09-11 |
Ｈ 朗德貝克公司 |
苯甲醯胺類
|
|
TW201427947A
(zh)
|
2012-10-12 |
2014-07-16 |
Lundbeck & Co As H |
環狀胺
|
|
WO2014061277A1
(fr)
|
2012-10-19 |
2014-04-24 |
第一三共株式会社 |
Conjugué anticorps-médicament produit par liaison par l'intermédiaire d'un lieur ayant une structure hydrophile
|
|
WO2014066532A1
(fr)
|
2012-10-23 |
2014-05-01 |
Bristol-Myers Squibb Company |
Association d'anticorps anti-kir et anti-ctla-4 pour le traitement du cancer
|
|
WO2014065402A1
(fr)
|
2012-10-26 |
2014-05-01 |
株式会社ペルセウスプロテオミクス |
Anticorps monoclonal anti-cd-40 humain, et utilisation correspondante
|
|
JP2016011258A
(ja)
|
2012-10-26 |
2016-01-21 |
株式会社ペルセウスプロテオミクス |
抗ヒトｃｄ４０モノクローナル抗体及びその利用
|
|
WO2014070934A1
(fr)
|
2012-10-30 |
2014-05-08 |
Apexigen, Inc. |
Anticorps anti-cd40 et procédés d'utilisation
|
|
WO2014074529A1
(fr)
*
|
2012-11-06 |
2014-05-15 |
The Board Of Regents Of The University Of Texas System |
Méthodes de traitement d'un cancer primaire et de la métastase cancéreuse
|
|
KR20150095668A
(ko)
|
2012-12-13 |
2015-08-21 |
아두로 바이오테크, 인코포레이티드 |
규정된 입체화학을 갖는 환식 퓨린 다이뉴클레오타이드를 포함하는 조성물, 그리고 이의 제조 방법 및 용도
|
|
EP2935211B1
(fr)
|
2012-12-18 |
2016-11-09 |
Actelion Pharmaceuticals Ltd. |
Dérivés d'indole carboxamide utilisés en tant qu'antagonistes du récepteur p2x7
|
|
AU2013361275B2
(en)
|
2012-12-19 |
2016-11-24 |
Amplimmune, Inc. |
Anti-human B7-H4 antibodies and their uses
|
|
CN110201155A
(zh)
*
|
2012-12-19 |
2019-09-06 |
得克萨斯州立大学董事会 |
哺乳动物的环二核苷酸信号通路的药物靶向
|
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
|
CA2896790C
(fr)
|
2013-01-22 |
2022-05-10 |
Actelion Pharmaceuticals Ltd |
Derives d'amides heterocycliques utilises comme antagonistes du recepteur p2x7
|
|
TWI599567B
(zh)
|
2013-03-14 |
2017-09-21 |
健生藥品公司 |
Ｐ２ｘ７調節劑
|
|
US10053463B2
(en)
|
2013-03-14 |
2018-08-21 |
Janssen Pharmaceutica Nv |
Substituted [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
|
|
TWI627174B
(zh)
|
2013-03-14 |
2018-06-21 |
比利時商健生藥品公司 |
Ｐ２ｘ７調控劑
|
|
EP3299391B1
(fr)
|
2013-03-14 |
2019-12-04 |
Genentech, Inc. |
Anticorps et immunoconjugués anti-b7-h4
|
|
JP6294953B2
(ja)
|
2013-03-14 |
2018-03-14 |
ヤンセン ファーマシューティカ エヌ．ベー． |
Ｐ２ｘ７調節物質
|
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
|
WO2014140374A2
(fr)
|
2013-03-15 |
2014-09-18 |
Novo Nordisk A/S |
Anticorps monovalents anti-cd27
|
|
US20140322236A1
(en)
|
2013-03-15 |
2014-10-30 |
Sdix, Llc |
Anti-human adora2a antibodies
|
|
EP2976361B1
(fr)
|
2013-03-18 |
2018-07-18 |
BiocerOX Products B.V. |
Anticorps humanisés (ox40) anti-cd134 et leurs utilisations
|
|
US20160084839A1
(en)
|
2013-04-02 |
2016-03-24 |
Marisa Dolled-Filhart |
Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
|
|
US9724408B2
(en)
|
2013-05-18 |
2017-08-08 |
Aduro Biotech, Inc. |
Compositions and methods for activating stimulator of interferon gene-dependent signalling
|
|
AU2014268298B2
(en)
|
2013-05-24 |
2019-01-17 |
Medlmmune, Llc |
Anti-B7-H5 antibodies and their uses
|
|
CA2913977C
(fr)
|
2013-05-31 |
2022-11-29 |
Sorrento Therapeutics, Inc. |
Proteines de liaison a l'antigene qui se lient a pd-1
|
|
SG11201509982UA
(fr)
|
2013-06-06 |
2016-04-28 |
Igenica Biotherapeutics Inc |
|
|
WO2014209168A1
(fr)
|
2013-06-24 |
2014-12-31 |
Kim Ruslan Zynsonovich |
Communicateur automobile
|
|
GB201311487D0
(en)
|
2013-06-27 |
2013-08-14 |
Alligator Bioscience Ab |
Bispecific molecules
|
|
RU2016107426A
(ru)
|
2013-08-02 |
2017-09-07 |
Адуро Байотек Холдингс, Юроуп Б.В. |
Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета
|
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
|
US10077305B2
(en)
|
2013-09-10 |
2018-09-18 |
Medimmune Limited |
Antibodies against PD-1 and uses thereof
|
|
KR20160065858A
(ko)
|
2013-10-21 |
2016-06-09 |
드렉셀유니버시티 |
만성 b형 간염 바이러스 감염을 치료하기 위한 스팅 효능제의 사용
|
|
ES2707057T3
(es)
|
2013-11-06 |
2019-04-02 |
Bristol Myers Squibb Co |
Combinación de anticuerpos anti-KIR y anti-CS1 para tratar el mieloma múltiple
|
|
GB201322583D0
(en)
|
2013-12-19 |
2014-02-05 |
Alligator Bioscience Ab |
Antibodies
|
|
AU2014368695A1
(en)
|
2013-12-20 |
2016-04-14 |
F. Hoffmann-La Roche Ag |
Combination therapy with an anti-ANG2 antibody and a CD40 agonist
|
|
EP3102604B1
(fr)
|
2014-02-04 |
2020-01-15 |
Pfizer Inc |
Combinaison d'un antagoniste de pd -1 et d'un agoniste de 4-1bb pour le traitement du cancer
|
|
EP2905282A1
(fr)
|
2014-02-05 |
2015-08-12 |
AXXAM S.p.A. |
Thiazole ou oxazole substituée en tant qu'antagonistes du récepteur P2X7
|
|
WO2015134988A1
(fr)
|
2014-03-07 |
2015-09-11 |
Bristol-Myers Squibb Company |
Procédé d'utilisation de polypeptides d'anticorps qui sont des antagonistes de cd40 pour traiter une affection intestinale inflammatoire (aii)
|
|
BR112016026993A2
(pt)
|
2014-05-21 |
2017-10-31 |
Kyowa Hakko Kirin Co Ltd |
combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
|
|
SMT202100116T1
(it)
|
2014-05-28 |
2021-05-07 |
Agenus Inc |
Anticorpi anti-gitr e metodi di utilizzo degli stessi
|
|
WO2015181267A1
(fr)
|
2014-05-29 |
2015-12-03 |
Spring Bioscience Corporation |
Anticorps anti-b7-h3 et leurs utilisations diagnostiques
|
|
PT3151921T
(pt)
|
2014-06-06 |
2019-11-21 |
Bristol Myers Squibb Co |
Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
|
|
WO2015188047A1
(fr)
|
2014-06-06 |
2015-12-10 |
University Of Maryland, Baltimore |
Anticorps monoclonaux anti-cd-137 présentant des capacités de liaison distinctes au fcγr pour le traitement d'un cancer ou d'une auto-immunité
|
|
EP3157563A1
(fr)
|
2014-06-23 |
2017-04-26 |
TheraMAB LLC |
Compositions et méthodes pour une immunothérapie efficace et sûre
|
|
JP2017519597A
(ja)
|
2014-07-09 |
2017-07-20 |
ノボ・ノルデイスク・エー／エス |
モータ駆動薬剤送達装置
|
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
|
EP3180087B1
(fr)
|
2014-08-12 |
2019-03-13 |
Alligator Bioscience AB |
Polythérapies utilisant des anticorps anti-cd40
|
|
AU2015303239A1
(en)
|
2014-08-14 |
2016-12-15 |
F. Hoffmann-La Roche Ag |
Combination therapy of antibodies activating human CD40 and antibodies against human PD-L1
|
|
WO2016028810A1
(fr)
|
2014-08-18 |
2016-02-25 |
Biogen Ma Inc. |
Anticorps anti-cd40 et leurs utilisations
|
|
US20170247455A1
(en)
|
2014-08-22 |
2017-08-31 |
Bristol-Myers Squibb Company |
Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
|
|
US10316093B2
(en)
|
2014-08-27 |
2019-06-11 |
Memorial Sloan Kettering Cancer Center |
Antibodies, compositions, and uses
|
|
AU2015308527C1
(en)
|
2014-08-29 |
2021-07-15 |
F. Hoffmann-La Roche Ag |
Combination therapy of tumor-targeted IL-2 variant immunocytokines and antibodies against human PD-L1
|
|
CN113698485A
(zh)
|
2014-09-12 |
2021-11-26 |
基因泰克公司 |
抗-b7-h4抗体及免疫缀合物
|
|
MX2017004311A
(es)
|
2014-10-03 |
2017-12-07 |
Dana Farber Cancer Inst Inc |
Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
SG11201703403TA
(en)
|
2014-10-27 |
2017-05-30 |
Agency Science Tech & Res |
Anti-tim-3 antibodies
|
|
GB201419094D0
(en)
|
2014-10-27 |
2014-12-10 |
Agency Science Tech & Res |
Anti-TIM-3-antibodies
|
|
ES2772307T3
(es)
|
2014-10-28 |
2020-07-07 |
Childrens Univ Hospital Tuebingen |
Tratamiento de pacientes pediátricos con LLA-PCB con un anticuerpo anti-kir
|
|
SG10201913099YA
(en)
|
2014-10-29 |
2020-02-27 |
Seattle Genetics Inc |
Dosage and administration of non-fucosylated anti-cd40 antibodies
|
|
US10626176B2
(en)
|
2014-10-31 |
2020-04-21 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind B7-H4
|
|
CA2964830C
(fr)
|
2014-11-06 |
2024-01-02 |
F. Hoffmann-La Roche Ag |
Anticorps anti-tim3 et procedes d'utilisation
|
|
WO2016094837A2
(fr)
|
2014-12-11 |
2016-06-16 |
Igenica Biotherapeutics, Inc. |
Anticorps anti-c10orf54 et leurs utilisations
|
|
EP3233191A1
(fr)
|
2014-12-16 |
2017-10-25 |
Invivogen |
Utilisation combinée d'un agent chimiothérapeutique et d'un dinucléotide cyclique pour le traitement du cancer
|
|
WO2016096174A1
(fr)
|
2014-12-16 |
2016-06-23 |
Invivogen |
Dinucléotides cycliques fluorés utilisables en vue de l'induction des cytokines
|
|
WO2016106004A1
(fr)
|
2014-12-23 |
2016-06-30 |
Full Spectrum Genetics, Inc. |
Nouveaux composés de liaison anti-b7h3 et leurs utilisations
|
|
WO2016111947A2
(fr)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Anticorps inhibiteurs d'interactions de tim-3:lilrb2 et leurs utilisations
|
|
JP6692826B2
(ja)
|
2015-03-10 |
2020-05-13 |
アドゥロ バイオテック，インク． |
「インターフェロン遺伝子刺激因子」依存性シグナル伝達の活性化のための組成物及び方法
|
|
US20180125876A1
(en)
*
|
2015-05-20 |
2018-05-10 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and Pharmaceutical Composition for Modulation Polarization and Activation of Macrophages
|
|
UA123701C2
(uk)
|
2015-08-13 |
2021-05-19 |
Мерк Шарп І Доум Корп. |
Циклічні динуклеотидні сполуки як агоністи sting
|
|
US10906930B2
(en)
|
2015-10-28 |
2021-02-02 |
Chinook Therapeutics, Inc. |
Compositions and methods for activating “stimulator of interferon gene”-dependent signalling
|
|
WO2017100305A2
(fr)
|
2015-12-07 |
2017-06-15 |
Opi Vi - Ip Holdco Llc |
Composition de conjugués d'agonistes-constructions d'anticorps et leurs procédés d'utilisation
|
|
US10723756B2
(en)
|
2016-01-11 |
2020-07-28 |
Innate Tumor Immunity Inc. |
Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
|
|
WO2017180769A1
(fr)
|
2016-04-13 |
2017-10-19 |
Capten Therapeutics Inc. |
Petites molécules pour le traitement immunogène du cancer
|
|
WO2018009466A1
(fr)
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
|
|
US20190345191A1
(en)
|
2016-08-31 |
2019-11-14 |
Innate Tumor Immunity, Inc. |
Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
|
|
UA125223C2
(uk)
|
2016-10-04 |
2022-02-02 |
Мерк Шарп І Доум Корп. |
СПОЛУКИ БЕНЗО[b]ТІОФЕНУ ЯК АГОНІСТИ STING
|
|
JOP20170188A1
(ar)
|
2016-11-25 |
2019-01-30 |
Janssen Biotech Inc |
ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
|
|
JOP20170192A1
(ar)
|
2016-12-01 |
2019-01-30 |
Takeda Pharmaceuticals Co |
داي نوكليوتيد حلقي
|
|
US20190328762A1
(en)
|
2016-12-20 |
2019-10-31 |
Merck Sharp & Dohme Corp. |
Combinations of pd-1 antagonists and cyclic dinucleotide sting agonists for cancer treatment
|
|
WO2018118665A1
(fr)
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Agonistes dinucléotidiques cycliques de sting pour le traitement du cancer
|
|
ES2891326T3
(es)
|
2017-01-27 |
2022-01-27 |
Janssen Biotech Inc |
Dinucleótidos cíclicos como agonistas de la STING
|
|
US11492367B2
(en)
|
2017-01-27 |
2022-11-08 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
JOP20190218A1
(ar)
|
2017-03-22 |
2019-09-22 |
Boehringer Ingelheim Int |
مركبات ثنائية النيوكليوتيدات حلقية معدلة
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
AR113224A1
(es)
|
2017-04-28 |
2020-02-19 |
Novartis Ag |
Conjugados de anticuerpo que comprenden un agonista de sting
|
|
US11466047B2
(en)
|
2017-05-12 |
2022-10-11 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
WO2018234807A1
(fr)
|
2017-06-22 |
2018-12-27 |
Curadev Pharma Limited |
Modulateurs hétérocycliques à petites molécules de sting humain
|
|
WO2018234808A1
(fr)
|
2017-06-22 |
2018-12-27 |
Curadev Pharma Limited |
Modulateurs à petites molécules de sting humain
|
|
JP2020524717A
(ja)
|
2017-06-22 |
2020-08-20 |
キュラデブ・ファーマ・リミテッドＣｕｒａｄｅｖ Ｐｈａｒｍａ Ｌｉｍｉｔｅｄ |
ヒトｓｔｉｎｇの小分子調節因子
|
|
CA3071538A1
(fr)
|
2017-08-04 |
2019-02-07 |
Merck Sharp & Dohme Corp. |
Agonistes benzo[b]thiophene de sting pour le traitement du cancer
|
|
EP3661499A4
(fr)
|
2017-08-04 |
2021-04-21 |
Merck Sharp & Dohme Corp. |
Combinaisons d'antagonistes de pd-1 et d'agonistes de sting benzo[b
|
|
CN107335049B
(zh)
*
|
2017-08-18 |
2019-10-18 |
中国药科大学 |
菊科类型环肽化合物作为cGAS-STING信号通路抑制剂的应用
|
|
US11638716B2
(en)
|
2017-08-31 |
2023-05-02 |
F-star Therapeutics, Inc. |
Compounds, compositions, and methods for the treatment of disease
|
|
WO2019051489A1
(fr)
|
2017-09-11 |
2019-03-14 |
Sperovie Biosciences, Inc. |
Composés, compositions et méthodes de traitement de maladie
|
|
CA3075751A1
(fr)
|
2017-09-15 |
2019-03-21 |
Aduro Biotech, Inc. |
Composes de pyrazolopyrimidinone et leurs utilisations
|
|
US12178851B2
(en)
|
2017-10-05 |
2024-12-31 |
Glaxosmithkline Intellectual Property Development Limited |
Methods for administering STING agonists
|
|
US20210238172A1
(en)
|
2017-10-05 |
2021-08-05 |
Glaxosmithkline Intellectual Property Development Limited |
Heterocyclic amides useful as protein modulators and methods of using the same
|